These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37225927)

  • 1. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
    Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
    Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?
    Morel P; Karras A; Porcher R; Belenfant X; Audard V; Rafat C; Hanouna G; Beaudreuil S; Vilain C; Hummel A; Terrier B; Pillebout E; Groh M; Jouenne R; Dhote R; Fain O; Ponsoye M; Noel N; Limal N; Puéchal X; Le Jeunne C; Guillevin L; Mouthon L; Régent A
    Rheumatology (Oxford); 2022 Oct; 61(10):4056-4064. PubMed ID: 35108368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
    Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
    J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
    Murakami C; Manoharan P; Carter-Monroe N; Geetha D
    Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial.
    Dirikgil E; van Leeuwen JR; Bredewold OW; Ray A; Jonker JT; Soonawala D; Remmelts HHF; van Dam B; Bos WJ; van Kooten C; Rotmans J; Rabelink T; Teng YKO
    BMJ Open; 2022 Sep; 12(9):e061339. PubMed ID: 36130755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series.
    Krishna R; De Giacomi F; Kumar N; Kalina P; Specks U; Baqir M
    J Clin Rheumatol; 2021 Mar; 27(2):64-72. PubMed ID: 31567753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.
    Geetha D; Sethi S; De Vriese AS; Specks U; Kallenberg CGM; Lim N; Spiera R; St Clair EW; Merkel PA; Seo P; Monach PA; Lepori N; Fessler BJ; Langford CA; Hoffman GS; Sharma R; Stone JH; Fervenza FC;
    Am J Nephrol; 2017; 46(3):231-238. PubMed ID: 28881339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
    Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
    Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.
    Roccatello D; Sciascia S; Murgia S; Quattrocchio G; Ferro M; De Simone E; Naretto C; Barreca A; Sammartino A; Rossi D; Fenoglio R
    Front Immunol; 2022; 13():777134. PubMed ID: 35401565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.
    Liu L; Lu H; Zou G; Wang H; Li J; Yang Y; Zhang J; Wang X; Li W; Zhuo L
    BMC Nephrol; 2023 Feb; 24(1):28. PubMed ID: 36755215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.
    Gérard M; de Boysson H; Morello R; Martin-Silva N; Leroux AC; Dumont A; Maigné G; Boutemy J; Khoy K; Mariotte D; Lobbedez T; Aouba A; Deshayes S
    Scand J Rheumatol; 2023 Mar; 52(2):161-173. PubMed ID: 35048797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study.
    Ysermans R; Busch MH; Aendekerk JP; Damoiseaux JGMC; van Paassen P
    J Transl Autoimmun; 2023; 6():100178. PubMed ID: 36589266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.